论文信息 - Casimersen: First Approval - 字舞流文

Casimersen: First Approval

[1] P. Shieh,et al. Casimersen treatment in eligible patients with Duchenne muscular dystrophy: safety, tolerability, and pharmacokinetics over 144 weeks of treatment , 2021 .

[2] E. Mercuri,et al. Duchenne muscular dystrophy , 2021, Nature Reviews Disease Primers.

[3] P. Shieh,et al. DMD – THERAPY P.288 Casimersen treatment in eligible patients with Duchenne muscular dystrophy: Safety, tolerability, and pharmacokinetics over 144 weeks of treatment , 2020, Neuromuscular Disorders.

[4] P. Ghosh,et al. Update on Muscular Dystrophies with Focus on Novel Treatments and Biomarkers , 2020, Current Neurology and Neuroscience Reports.

[5] A. Aartsma-Rus,et al. Therapeutic developments for Duchenne muscular dystrophy , 2019, Nature Reviews Neurology.

[6] S. Pandya,et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management , 2018, The Lancet Neurology.

[7] T. Yokota,et al. An Overview of Recent Advances and Clinical Applications of Exon Skipping and Splice Modulation for Muscular Dystrophy and Various Genetic Diseases. , 2018, Methods in molecular biology.

[8] Form 8-K,et al. UNITED STATES SECURITIES AND EXCHANGE COMMISSION , 2017 .

[9] A. Ossipov,et al. Duchenne muscular dystrophy , 2004 .